TRX103 + cyclophosphamide

TRX103 + cyclophosphamide is an experimental combination therapy involving TRX103, an investigational agent, and cyclophosphamide, a well-established alkylating antineoplastic and immunosuppressive small molecule. TRX103 is being studied for immune modulation in Crohn's disease; its mechanism likely involves immune system regulation, though its precise target is not specified in available data. Cyclophosphamide acts as a DNA-alkylating agent, forming DNA crosslinks to inhibit cancer cell proliferation and possesses immunosuppressive properties. The combination aims to leverage immune modulation for therapeutic effect in inflammatory diseases such as Crohn's disease, expanding upon cyclophosphamide’s historical antitumor and immunosuppressive utility[5].